{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026409","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.000953+00:00","generated_at":"2026-05-15T14:52:51.981149+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioXcel Therapeutics raises $7.8M in registered direct offering and amends prior warrants","bullets":["Sold 2,480,294 common shares and pre-funded warrants for 2,020,491 shares at combined $1.739/unit, plus accompanying warrants.","Gross proceeds ~$7.8M; placement agent fees 6% cash plus 180,031 warrants at $2.0175.","Warrant amendment reduces exercise price to $1.614 on 1,385,083 prior warrants and extends term to 5 years; investor paid ~$173k.","Proceeds used for working capital and general corporate purposes.","Offering closed March 11, 2026; common stock trades on Nasdaq under BTAI."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026409","json":"https://secwatch.observer/filing/0001104659-26-026409.json","markdown":"https://secwatch.observer/filing/0001104659-26-026409.md","text":"https://secwatch.observer/filing/0001104659-26-026409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/tm268136d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:52:51.981149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2de0b5d0b625b2a7a60faa4a07a09050cc8c5300","claim":"BioXcel Therapeutics, Inc. entered into Purchase Agreement with the Purchaser valued at approximately $7.8 million (effective 2026-03-10).","evidence_excerpt":"On March 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchaser"},{"label":"Value","value":"approximately $7.8 million"},{"label":"Effective","value":"2026-03-10"}],"fact_type":"material_agreement"},{"claim_id":"cc4bd5daec59e29d6cb5c180528740a5ef72c01d","claim":"BioXcel Therapeutics, Inc. amended Warrant Amendment Agreement with the Purchaser valued at approximately $173,135 (effective 2026-03-10).","evidence_excerpt":"In connection with the Offering, pursuant to the terms of a Warrant Amendment Agreement, dated as of March 10, 2026 (the “Warrant Amendment Agreement”), the exercise price of certain outstanding warrants issued on March 27, 2024 and November 25, 2024 to purchase up to an aggregate of 1,385,083 shares of Common Stock held by the Purchaser was reduced to $1.614 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchaser"},{"label":"Value","value":"approximately $173,135"},{"label":"Effective","value":"2026-03-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}